Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a Kezar Life Sciences 10-K can feel like navigating a dense immunology journal. Clinical-stage biotech disclosures pack pages with trial endpoints, burn-rate tables and licensing clauses鈥攅xactly the data you need yet rarely have time to dig for. If you have ever Googled 鈥淜ezar Life Sciences SEC filings explained simply鈥� or asked, 鈥淲here do I find Kezar Life Sciences insider trading Form 4 transactions?鈥� this page is built for you.
Stock Titan鈥檚 AI reads every submission the moment it hits EDGAR, then highlights what matters: from Form 4 insider trades鈥攄elivered as 鈥淜ezar Life Sciences Form 4 insider transactions real-time鈥濃�攖o the latest 鈥淜ezar Life Sciences quarterly earnings report 10-Q filing.鈥� Want to know when management discloses a new clinical milestone in an 8-K? Our engine tags that section, so 鈥淜ezar Life Sciences 8-K material events explained鈥� becomes a two-minute read. Annual reports? You鈥檒l see 鈥淜ezar Life Sciences annual report 10-K simplified,鈥� complete with plain-English summaries of R&D spend and cash runway.
Professionals use this hub to: monitor 鈥淜ezar Life Sciences executive stock transactions Form 4,鈥� compare pipeline outlays quarter over quarter, and review 鈥淜ezar Life Sciences proxy statement executive compensation鈥� without wading through boilerplate. Whether you鈥檙e tracking biotech-specific risk factors, valuation-moving trial data, or seeking a concise 鈥淜ezar Life Sciences earnings report filing analysis,鈥� our AI-powered summaries, real-time alerts and full-text search deliver the insight you need鈥攆ast.
Kezar Life Sciences reported continued operating losses while reducing cash burn. For the six months ended June 30, 2025 the company recorded a $30.3 million net loss versus $43.2 million a year earlier; the three鈥憁onth loss was $13.7 million. Cash, cash equivalents and marketable securities totaled $100.8 million, and management believes these resources are sufficient to fund operations for at least 12 months from issuance of the financial statements. The company carried an accumulated deficit of $464.8 million.
Operating changes reflect a strategic refocus: research and development expense fell to $21.8 million for six months (from $33.5 million) after termination or completion of several trials, including the PALIZADE program and discontinuation of KZR鈥�261. Kezar recognized an upfront $7.0 million payment from its Everest collaboration and has potential milestone payments up to $125.5 million plus tiered royalties. Debt outstanding totaled a principal of $7.391 million (net debt $7.921 million) with principal repayments scheduled through 2026. In July 2025 the FDA removed a partial clinical hold on the completed PORTOLA trial and Kezar requested a Type C meeting to discuss AIH development plans.
Kezar Life Sciences reported it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The current report furnishes that press release as Exhibit 99.1 and incorporates it by reference. The filing also includes a Cover Page Interactive Data File as Exhibit 104.
The company states that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated. No additional financial detail or analysis is included within this report.
Form 4 Filing Details: Micki Klearman, Director at Kezar Life Sciences (KZR), received a stock option grant on June 18, 2025. The transaction involves the acquisition of 5,000 stock options with the following key terms:
- Exercise price set at $4.46 per share
- Options expire on June 17, 2035
- 100% vesting scheduled for June 18, 2026, contingent on continued service
- Underlying security is Common Stock
This Form 4 filing, signed by Marc Belsky as Attorney-in-Fact on June 23, 2025, represents a standard director compensation equity grant. The options provide Klearman with the right to purchase 5,000 shares of Kezar Life Sciences common stock upon vesting, aligning the director's interests with those of shareholders through long-term equity ownership potential.
Kezar Life Sciences Director Michael Kauffman received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative security details include:
- Grant of 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
The transaction represents a standard director compensation grant. Kauffman holds the options directly, with no indirect beneficial ownership reported. The filing was signed by Marc Belsky as attorney-in-fact on June 23, 2025.
Director Courtney Wallace of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- 100% vesting scheduled for June 18, 2026, contingent on continued service
- Options expire on June 17, 2035
This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The Form 4 was filed within the required reporting timeline, signed by Marc Belsky as attorney-in-fact on June 23, 2025.
Elizabeth Garner, Director at Kezar Life Sciences (KZR), received a stock option grant on June 18, 2025. The derivative securities transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This Form 4 filing represents a standard director compensation equity grant. The options provide Garner with the right to purchase company shares at a fixed price, aligning her interests with shareholders over the long term. The one-year cliff vesting schedule incentivizes retention and continued service on the board.
Director Graham K. Cooper of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This grant represents standard director compensation and was filed within the required reporting timeframe. The options provide Cooper with the right to purchase Kezar shares at a fixed price over the next decade, aligning his interests with shareholders' long-term value creation.
FAQ
What is the current stock price of Kezar Life Sciences (KZR)?
What is the market cap of Kezar Life Sciences (KZR)?
